NVS Jan 2025 125.000 call
| Previous close | 1.3000 |
| Open | 1.3000 |
| Bid | 1.2500 |
| Ask | 2.5500 |
| Strike | 125.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.3000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
- GlobeNewswire
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric heart failure is an important cause of childhood morbidity and mortality – up to a third of all pediatric cardiac admissions are due to heart failure; these hospitalizations are associated with a 20-fold increase in the risk of death1,2 The positive opinion is based on final data from the 52-week Phase I
- Zacks
Why Novartis (NVS) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
- Motley Fool
What Bear Market? These 2 Winning Stocks Are Still Worth Buying.
The stock market is in a precarious place. The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022. The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples.
